| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
PKC-β
The compound specifically targets protein kinase C (PKC), primarily the PKCbeta isoform. It functions as a pseudo-substrate, binding to the substrate-binding pocket of the kinase domain but lacking a serine/threonine residue for phosphorylation. This binding prevents access of the true physiological substrates, thereby blocking kinase activity. |
|---|---|
| ln Vitro |
In cell-free assays, PKC beta pseudosubstrate competitively inhibits PKC activity. It binds to the active site with high affinity, mimicking the interaction of a protein substrate but without being phosphorylated. This results in potent inhibition of the kinase's ability to transfer a phosphate group to its natural targets, with an IC50 of approximately 0.5 microM.
|
| ln Vivo |
In vivo studies using this compound have demonstrated its ability to block PKC-dependent signaling pathways in cells and tissues. By inhibiting PKC, it can modulate various cellular functions, including cell survival, proliferation, and synaptic plasticity. Its cell-permeable nature makes it a valuable tool for dissecting the role of PKC in complex physiological processes.
|
| Enzyme Assay |
Cell-free PKC activity assays are performed using purified PKC enzyme, a synthetic peptide substrate (e.g., myelin basic protein), ATP, and varying concentrations of the pseudosubstrate. The reaction is incubated, and the phosphorylated product is quantified by measuring the incorporation of radioactive [gamma-32P]ATP using a scintillation counter or via a non-radioactive ELISA-based method.
|
| Cell Assay |
Cellular assays are performed in cell lines of interest (e.g., fibroblasts, neurons). Cells are incubated with PKC beta pseudosubstrate for 2-24 hours. The inhibition of PKC activity is assessed by lysing the cells and measuring the phosphorylation status of a known PKC substrate (e.g., MARCKS) via Western blot or by performing an in vitro kinase assay on the cell lysates.
|
| Animal Protocol |
In vivo studies are conducted in rodent models (e.g., mice). The PKC beta pseudosubstrate is typically administered via intrathecal, intracerebroventricular, or intraperitoneal injection. Following treatment, target tissues are harvested. PKC activity is assessed by Western blot analysis of phosphorylated PKC substrates, and the levels of downstream signaling proteins are measured to evaluate the extent and duration of target inhibition.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of PKC beta pseudosubstrate are characteristic of a cell-permeable peptide. It is typically administered via injection and is expected to have a short circulating half-life due to proteolytic degradation. Its primary utility lies in its rapid, direct inhibition of PKC in cellular and acute in vivo models.
|
| Toxicity/Toxicokinetics |
Toxicological data is limited to the effects of PKC inhibition. As a research tool, it is generally well-tolerated in acute studies. Standard safety precautions for handling peptides and laboratory chemicals apply. Chronic inhibition of PKC could have profound physiological effects, but long-term toxicology is not typically evaluated for this tool.
|
| References | |
| Additional Infomation |
PKC beta pseudosubstrate is a critical chemical probe for studying the role of PKC, specifically the beta isoform, in various signal transduction pathways. It is distinct from small molecule inhibitors because of its high specificity and competitive mechanism, making it invaluable for validating PKC as a drug target in disease models. It is for research use only.
|
| Molecular Formula |
C177H294N62O38S3
|
|---|---|
| Molecular Weight |
3994.81588983536
|
| Exact Mass |
3993.217
|
| CAS # |
172308-76-8
|
| PubChem CID |
90488712
|
| Appearance |
White to off-white solid powder
|
| LogP |
-14.7
|
| Hydrogen Bond Donor Count |
64
|
| Hydrogen Bond Acceptor Count |
55
|
| Rotatable Bond Count |
150
|
| Heavy Atom Count |
280
|
| Complexity |
9160
|
| Defined Atom Stereocenter Count |
32
|
| SMILES |
S(C[C@@H](C(N[C@@H](CCCNC(=N)N)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@H](C(N[C@@H](CCSC)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)O)CCCCN)=O)CCCCN)=O)CC1=CNC2C=CC=CC1=2)=O)CCCCN)=O)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)=O)CCC(N)=O)=O)CC1C=CC=CC=1)=O)CC1=CNC2C=CC=CC1=2)=O)[C@@H](C)CC)=O)CCCCN)=O)[C@@H](C)CC)=O)=O)=O)N)SC[C@@H](C(N[C@H](C(N[C@H](C(N[C@@H](C)C(N[C@H](C(N[C@H](C(NCC(N[C@@H](C)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(=O)O)C(C)C)=O)CC(N)=O)=O)CCCCN)=O)CCC(N)=O)=O)CCCNC(=N)N)=O)CC(C)C)=O)=O)=O)CCCCN)=O)CCCNC(=N)N)=O)=O)CC1C=CC=CC=1)=O)CCCNC(=N)N)=O)N
|
| InChi Key |
KIWJPYSSLFMLBZ-OSCDWKIESA-N
|
| InChi Code |
InChI=1S/C177H294N62O38S3/c1-12-96(7)140(168(272)228-114(54-28-34-73-182)159(263)238-141(97(8)13-2)169(273)236-130(86-103-90-210-109-49-23-21-47-105(103)109)165(269)232-128(84-101-44-18-15-19-45-101)163(267)226-122(63-66-134(187)241)157(261)234-131(87-136(189)243)166(270)223-119(60-40-79-207-176(199)200)149(253)220-118(59-39-78-206-175(197)198)151(255)227-124(68-81-278-11)158(262)219-112(52-26-32-71-180)153(257)233-129(85-102-89-209-108-48-22-20-46-104(102)108)164(268)221-111(51-25-31-70-179)152(256)229-125(170(274)275)55-29-35-74-183)239-160(264)123(64-67-135(188)242)225-148(252)116(57-37-76-204-173(193)194)215-144(248)106(184)92-279-280-93-107(185)145(249)216-117(58-38-77-205-174(195)196)155(259)231-127(83-100-42-16-14-17-43-100)161(265)213-99(10)143(247)214-115(56-36-75-203-172(191)192)147(251)217-110(50-24-30-69-178)146(250)211-91-138(245)212-98(9)142(246)230-126(82-94(3)4)162(266)222-120(61-41-80-208-177(201)202)150(254)224-121(62-65-133(186)240)156(260)218-113(53-27-33-72-181)154(258)235-132(88-137(190)244)167(271)237-139(95(5)6)171(276)277/h14-23,42-49,89-90,94-99,106-107,110-132,139-141,209-210H,12-13,24-41,50-88,91-93,178-185H2,1-11H3,(H2,186,240)(H2,187,241)(H2,188,242)(H2,189,243)(H2,190,244)(H,211,250)(H,212,245)(H,213,265)(H,214,247)(H,215,248)(H,216,249)(H,217,251)(H,218,260)(H,219,262)(H,220,253)(H,221,268)(H,222,266)(H,223,270)(H,224,254)(H,225,252)(H,226,267)(H,227,255)(H,228,272)(H,229,256)(H,230,246)(H,231,259)(H,232,269)(H,233,257)(H,234,261)(H,235,258)(H,236,273)(H,237,271)(H,238,263)(H,239,264)(H,274,275)(H,276,277)(H4,191,192,203)(H4,193,194,204)(H4,195,196,205)(H4,197,198,206)(H4,199,200,207)(H4,201,202,208)/t96-,97-,98-,99-,106-,107-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,139-,140-,141-/m0/s1
|
| Chemical Name |
(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2R)-2-amino-3-[[(2R)-2-amino-3-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-oxopropyl]disulfanyl]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]hexanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanoyl]amino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2503 mL | 1.2516 mL | 2.5032 mL | |
| 5 mM | 0.0501 mL | 0.2503 mL | 0.5006 mL | |
| 10 mM | 0.0250 mL | 0.1252 mL | 0.2503 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
